Diffusion Pharmaceuticals Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Diffusion Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DFFN, but not buy additional shares or sell existing shares.
View analyst ratings for Diffusion Pharmaceuticals or view top-rated stocks.

Diffusion Pharmaceuticals' stock was trading at $15.25 on January 1st, 2022. Since then, DFFN shares have decreased by 54.8% and is now trading at $6.89.
View the best growth stocks for 2022 here.

Diffusion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Diffusion Pharmaceuticals.

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) announced its earnings results on Thursday, May, 12th. The company reported ($2.22) EPS for the quarter, missing analysts' consensus estimates of ($1.75) by $0.47.
View Diffusion Pharmaceuticals' earnings history.

Diffusion Pharmaceuticals's stock reverse split on the morning of Tuesday, April 19th 2022. The 1-50 reverse split was announced on Tuesday, April 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 19th 2022. An investor that had 100 shares of Diffusion Pharmaceuticals stock prior to the reverse split would have 2 shares after the split.

Some companies that are related to Diffusion Pharmaceuticals include 9 Meters Biopharma (NMTR), Akari Therapeutics (AKTX), Catalyst Biosciences (CBIO), Kazia Therapeutics (KZIA), LifeVantage (LFVN), Infinity Pharmaceuticals (INFI), Athenex (ATNX), Oncotelic Therapeutics (OTLC), iBio (IBIO), eFFECTOR Therapeutics (EFTR), Frequency Therapeutics (FREQ), DiaMedica Therapeutics (DMAC), Oncternal Therapeutics (ONCT), Processa Pharmaceuticals (PCSA) and SELLAS Life Sciences Group (SLS).
View all of DFFN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novan (NOVN), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE) and Enerplus (ERF).

Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."

Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DFFN stock can currently be purchased for approximately $6.89.

Diffusion Pharmaceuticals (NASDAQ:DFFN) has a market capitalization of $14.06 million. The company earns $-24,100,000.00 in net income (profit) each year or ($12.22) on an earnings per share basis.

Diffusion Pharmaceuticals employs 16 workers across the globe.

Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The official website for Diffusion Pharmaceuticals is www.diffusionpharma.com. The company can be reached via phone at (434) 220-0718, via email at investorrealtions@diffusionpharma.com, or via fax at 434-220-0722.